JPRN-UMIN000004639已完成1 期
Phase I /II and Pharmacological Clinical Study of Combination Chemotherapy with Irinotecan(CPT-11) and Erlotinib(Tarceva) for Recurrent Lung Cancer - Phase I /II and Pharmacological Clinical Study of Combination Chemotherapy with CPT-11 and Erlotinib for Recurrent Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Active infection. Severe DM. Severe heart disease, angina, myocadial infarction before 3 month. Active peptic ulcer. Concomitant malignancy. Severe neural disease. Severe comorbidity. Interstitial pneumonia in chest CT. Symptomatic brain metastasis. Severe ascites. Severe pleural effusion. Severe pericardial effusion. Impaired blodd coagulation. Pregnant, potential pregnant, or lactating. Severe drug hypersensitivity. Judged inappropriate for the trial by the doctor in charge
研究者
相似试验
招募中
1 期
Phase I/II trial for safety and pharmacokinetics of ENDOPIN in healthy adults and patients with paiPhase 1 part: Healthy adult male Phase 2 part: Postoperative pain patientspostoperative painD010149JPRN-jRCT2051220144akajima Takako46
进行中（未招募）
1 期
Phase I/II clinical study of AKP-022 in healthy Japanese premenopausal female subjectsHealthy Japanese premenopausal femalesJPRN-jRCT2071230042Hozumi Hiroyasu48
进行中（未招募）
1 期
Study of Recombinant Factor IX Product, IB1001, in Subjects with Haemophilia BEUCTR2007-005100-41-GBAptevo Europe Limited80
已完成
3 期
A clinical trial to study the effects of Recombinant Factor IX product IB-1001 in patients with Hemophilia-BCTRI/2011/04/001676Aptevo Bio Therapeutics LLC80
进行中（未招募）
不适用
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia BMedDRA version: 14.1Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 10010331 - Congenital, familial and genetic disordersHemophilia BEUCTR2007-005100-41-PLInspiration Biopharmaceuticals80